CoChat
Sign Up
Cited by 293Renin-Angiotensin System StudiesBlood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.

Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetes

Jandeleit-Dahm, Karin AM, Tikellis, Christos, Reid, Christopher M, Johnston, Colin I, Cooper, Mark E·2005·Journal of Hypertension
DOI 10.1097/01.hjh.0000160198.05416.72
Open this paper in CoChat — free account

Abstract

Recent trials have suggested that inhibitors of the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), may reduce the incidence of new-onset diabetes in patients with or without hypertension and at high risk of developing diabetes. In this review, we critically evaluate the evidence from recent clinical trials for such a potential preventive effect of ACE inhibitors and ARBs, including a meta-analysis of these recent trials. The reduced incidence of diabetes in patients at high risk of developing diabetes by ACE inhibitors or ARBs has been explained by haemodynamic effects, such as improved delivery of insulin and glucose to the peripheral skeletal muscle, and non-haemodynamic effects, including direct effects on glucose transport and insulin signalling pathways, all of which decrease insulin resistance. There is now evidence that the pancreas may contain an in situ active RAS, which appears to be upregulated in an animal model of type 2 diabetes. Thus, ACE inhibitors and ARBs may act by attenuating the deleterious effect of angiotensin II on vasoconstriction, fibrosis, inflammation, apoptosis and beta-cell death in the pancreas, thereby protecting a critical beta-cell mass essential for insulin production. New evidence is presented that ACE inhibitors and ARBs may delay or prevent the development of insulin resistance and diabetes, for which novel mechanisms are suggested. The actions of agents that interrupt the RAS on insulin resistance, obesity and diabetes warrant further investigation in other animal models. Prospective clinical studies with the primary endpoint of the prevention of diabetes are now indicated to (i) further explore whether the inhibitors of the RAS are superior compared to other antihypertensive agents such as calcium channel blockers (CCBs) and (ii) to evaluate the potential beneficial effects of combination antihypertensive regimens on the development of diabetes.

Overview

Integrity signals

Registry

Crossref · 10.1097/01.hjh.0000160198.05416.72

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

1 of the 89 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. 2000, Heart Outcomes Prevention Evaluation Study Investigators., Lancet, 355, 253
  2. 1999, National Intervention Cooperative Study in Elderly Hypertensives Study Group., Hypertension, 34, 1129
  3. 1997, Diabetes C, are, 20, 1183

Cited by

Sorted by citations

Related

Metadata

Authors
Jandeleit-Dahm, K. A., Tikellis, C., Reid, C. M., Johnston, C. I., & Cooper, M. E.
Affiliations
Baker Heart and Diabetes Institute (AU)
ORCID
Venue
Journal of Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2005-03
Volume
23
Issue
3
Pages
463-473
ISSN
0263-6352 (ISSN-L)
DOI
10.1097/01.hjh.0000160198.05416.72
OpenAlex
W2048359273
Cited by
293
References
89
Citations by year
2026: 2 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 11 · 2019: 7 · 2018: 15 · 2017: 7 · 2016: 3 · 2015: 10 · 2014: 14 · 2013: 8 · 2012: 17
FWCI
6.04
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes prevention, new-onset diabetes, insulin resistance, beta-cell death, angiotensin II, hypertension, obesity, antihypertensive drugs, calcium channel blockers, combination antihypertensive therapy
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 2, Humans, Hypertension, Renin-Angiotensin System, Incidence, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review